Single-arm phase 1b study | Venetoclax Plus Gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia.
1 Aug, 2022 | 11:46h | UTC
Commentary on Twitter
? Venetoclax plus gilteritinib yields modified composite complete response of 75% in FLT3-mutated relapsed/refractory #AcuteMyeloidLeukemia
Read in #JCO ➡️ https://t.co/L7wxJ63qv9 #AML #leusm @Daver_Leukemia @jaltmanmd pic.twitter.com/ksXw1DNMsE
— Journal of Clinical Oncology (@JCO_ASCO) July 29, 2022